Aragon Pharmaceuticals, Inc.
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Subsidiary
- Established
- 2009-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
32
Active:20
Completed:9
Trial Phases
3 Phases
Phase 1:22
Phase 2:1
Phase 3:5
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (28 trials with phase data)โข Click on a phase to view related trials
Phase 1
22 (78.6%)Phase 3
5 (17.9%)Phase 2
1 (3.6%)An Expanded Access Protocol for Apalutamide Treatment of Participants With Non-Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Prostatic Neoplasms
- First Posted Date
- 2018-05-14
- Last Posted Date
- 2023-12-13
- Lead Sponsor
- Aragon Pharmaceuticals, Inc.
- Registration Number
- NCT03523338
- Locations
- ๐ง๐ท
Ynova Pesquisa Clinica, Florianopolis, Brazil
๐ง๐ทInstituto de Educacao, Pesquisa e Gestao em Saude Instituto Americas (COI), Rio de Janeiro, Brazil
๐ง๐ทEnsino e Terapia de Inovacao Clinica AMO - Etica, Salvador, Brazil
A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer
Phase 1
Recruiting
- Conditions
- Prostatic Neoplasms, Castration-Resistant
- Interventions
- First Posted Date
- 2015-10-30
- Last Posted Date
- 2025-07-18
- Lead Sponsor
- Aragon Pharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT02592317
- Locations
- ๐ฒ๐ฉ
Arensia Exploratory Medicine, Chisinau, Moldova, Republic of
๐ช๐ธHosp Univ Vall D Hebron, Barcelona, Spain
๐ช๐ธHosp. Virgen Del Rocio, Sevilla, Spain
A JNJ-56021927 (ARN-509; Apalutamide) QT/QTc Study
- First Posted Date
- 2015-10-19
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- Aragon Pharmaceuticals, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT02578797
An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
Phase 3
Active, not recruiting
- Conditions
- Prostatic Neoplasms
- Interventions
- Radiation: 74-80 Grays (units of radiation)
- First Posted Date
- 2015-08-24
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- Aragon Pharmaceuticals, Inc.
- Target Recruit Count
- 1503
- Registration Number
- NCT02531516
A Study to Evaluate the Pharmacokinetics of JNJ-56021927 in Participants With Mild or Moderate Hepatic Impairment Compared With Participants With Normal Hepatic Function
- First Posted Date
- 2015-08-17
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Aragon Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT02524717
- Prev
- 1
- 2
- 3
- 4
- Next
News
No news found